98,398 Cytokinetics, Incorporated $CYTK Shares Bought by Voya Investment Management LLC

Voya Investment Management LLC raised its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 26.7% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 467,096 shares of the biopharmaceutical company’s stock after acquiring an additional 98,398 shares during the period. Voya Investment Management LLC’s holdings in Cytokinetics were worth $30,786,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. Physician Wealth Advisors Inc. lifted its holdings in shares of Cytokinetics by 810.2% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 446 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 397 shares during the period. V Square Quantitative Management LLC grew its holdings in Cytokinetics by 71.5% during the third quarter. V Square Quantitative Management LLC now owns 458 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 191 shares during the period. Integrated Wealth Concepts LLC acquired a new stake in Cytokinetics during the second quarter worth about $36,000. Manchester Capital Management LLC acquired a new stake in Cytokinetics during the third quarter worth about $43,000. Finally, Allworth Financial LP raised its position in Cytokinetics by 35.6% during the third quarter. Allworth Financial LP now owns 732 shares of the biopharmaceutical company’s stock valued at $48,000 after acquiring an additional 192 shares in the last quarter.

Insiders Place Their Bets

In related news, CEO Robert I. Blum sold 97,926 shares of the company’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $69.33, for a total value of $6,789,209.58. Following the completion of the transaction, the chief executive officer owned 385,320 shares of the company’s stock, valued at approximately $26,714,235.60. This represents a 20.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director B. Parshall sold 5,000 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $71.48, for a total value of $357,400.00. Following the transaction, the director owned 10,784 shares in the company, valued at $770,840.32. This represents a 31.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 201,032 shares of company stock worth $13,320,502. 2.60% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on CYTK shares. Needham & Company LLC boosted their price target on Cytokinetics from $102.00 to $112.00 and gave the company a “buy” rating in a report on Friday, August 7th. HC Wainwright restated a “buy” rating and issued a $140.00 price objective on shares of Cytokinetics in a research report on Monday, October 19th. Barclays raised their price objective on shares of Cytokinetics from $95.00 to $110.00 and gave the stock an “overweight” rating in a research note on Thursday, August 13th. Royal Bank Of Canada lifted their target price on shares of Cytokinetics from $112.00 to $113.00 and gave the company an “outperform” rating in a report on Thursday, October 8th. Finally, JPMorgan Chase & Co. cut their target price on shares of Cytokinetics from $103.00 to $100.00 and set an “overweight” rating for the company in a report on Friday. Nineteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Cytokinetics currently has a consensus rating of “Moderate Buy” and a consensus price target of $106.50.

Get Our Latest Analysis on CYTK

Cytokinetics Stock Performance

Shares of Cytokinetics stock opened at $50.76 on Friday. The firm has a 50-day simple moving average of $61.89 and a two-hundred day simple moving average of $69.46. Cytokinetics, Incorporated has a fifty-two week low of $50.32 and a fifty-two week high of $88.31. The company has a market cap of $7.07 billion, a P/E ratio of -8.40 and a beta of 0.45.

Cytokinetics (NASDAQ:CYTK – Get Free Report) last posted its earnings results on Wednesday, November 4th. The biopharmaceutical company reported ($1.37) EPS for the quarter, beating analysts’ consensus estimates of ($1.43) by $0.06. The business had revenue of $47.56 million for the quarter, compared to analyst estimates of $41.88 million. During the same quarter last year, the business earned ($2.55) earnings per share. Cytokinetics’s revenue was up 2356.5% on a year-over-year basis. Equities research analysts forecast that Cytokinetics, Incorporated will post -5.85 EPS for the current year.

Cytokinetics Profile

(Free Report)

Cytokinetics is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. Its research centers on therapies for conditions involving impaired cardiac muscle performance. The company’s work includes aficamten, a cardiac myosin inhibitor developed for hypertrophic cardiomyopathy, and other drug candidates designed to affect muscle contraction. Cytokinetics conducts research and clinical development through programs that may involve patients and collaborators in multiple countries.

Further Reading

Want to see what other hedge funds are holding CYTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report).

Institutional Ownership by Quarter for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.